The Filing Desk

NeuroPace

NPCE · Nasdaq · Health Care · Financials, fiscal 2020 to 2025

NPCE · Last close · November 19, 2026
$8.14
Value NeuroPace yourself

NeuroPace's revenue rose 25.1% to $100 million in fiscal 2025. Its operating margin was −16.3%, up from −27.1% a year earlier. Free cash flow was −$11 million. It paid out $50 million in dividends and buybacks. The diluted share count rose 12.3%.

NEUROPACE, INC. Latest fiscal year ended December 31, 2025 10-K filed March 3, 2026 · 0001528287-26-000011 Updated
Revenue
$100M
25.1%
Operating margin
−16.3%
10.8 pts
Net income
−$22M
 
Free cash flow
−$11M
 
Return on capital
−81.8%
50.7 pts
Market cap
$279M
Nov 19 close
P/E
—
Loss: no P/E

Operating margin is operating income as a share of revenue. Free cash flow is cash from operations minus capital spending. Return on capital is after-tax operating income as a share of the money invested in the business: debt plus equity, minus cash. Market cap is the last closing share price times the latest diluted share count, so it is approximate. P/E is the last close divided by diluted earnings per share over the last four quarters, or the latest fiscal year where the quarters aren't available; there is none when the company made a loss.

Charts show fiscal years, from the 10-K filings.

What NeuroPace does

NeuroPace is a medical device company that treats epilepsy. Its RNS System is an implanted device that watches the brain's electrical activity, recognizes patterns that come before a seizure and sends small electrical pulses to stop it. Clinicians set up each patient's device. The company says it is the only commercially available device that records continuous brain activity data and lets clinicians check patients remotely.

The RNS System can be marketed in the United States only for adults with drug-resistant focal epilepsy, which is epilepsy that medicines don't control and that starts in one part of the brain. The company says this system is its primary source of revenue. As of December 31, 2025, over 8,000 patients had received the RNS System.

NeuroPace is seeking approval for more uses, which would let it reach more of the people with drug-resistant epilepsy over time.

Its biggest risks, as it describes them

  • It relies on one product, the RNS System, which can be marketed only in the U.S. for adults with drug-resistant focal epilepsy.
  • If it can't sell the system cost-effectively and win wider acceptance, its sales and growth would suffer.
  • Factors outside its control may disrupt manufacturing of the RNS System.
  • It may not forecast customer demand accurately.
From NeuroPace's annual report on Form 10-K, filed March 3, 2026, in our words; the 10-K has the full description and every risk factor. Updated with each new annual report.

Income statement

Revenue and net income
US$ billions, fiscal years; net losses in red. Revenue on the left axis, net income on the right; zero is the same line on both.
Revenue (left axis)Net income (right axis)
Gross profit, R&D and operating income
US$ billions, fiscal years. Gross profit is revenue minus the cost of what was sold; research and development is one of the costs paid from it; what remains after all operating costs is operating income. Losses in red.
Gross profitResearch and developmentOperating income
Margins
Percent of revenue
GrossOperatingNetFree cash flow

NeuroPace lost money in fiscal 2025: a net loss of $22 million.

Diluted earnings per share
US$ per share, fiscal years, restated for any stock splits; loss years in red.

Returns on capital

Return on capital and on equity
Percent. Return on capital is after-tax operating income over the money invested in the business (debt plus equity, minus cash); return on equity is net income over shareholders' equity. Both use the average of opening and closing balances.
Return on capitalReturn on equity

Balance sheet

Cash and debt
US$ billions, at each fiscal year end. Debt includes finance leases.
Cash and short-term investmentsDebt
Assets, liabilities and equity
US$ billions, at each fiscal year end. Assets equal liabilities plus equity; negative equity in red.
Total assetsTotal liabilitiesShareholders' equity
Debt and liquidity ratios
Times. Debt to equity, current assets over current liabilities, and net debt over EBITDA (a full year's).
Debt to equityCurrent ratioNet debt to EBITDA

Five years at a glance

Fiscal year endFY21FY22FY23FY24FY25
Cash and short-term investments11677665361
Debt incl. finance leases5053576059
Net debt (negative means net cash)−66−25−107−2
Net debt to EBITDA—————
Debt to equity0.7x1.5x2.8x7.4x3.1x
Interest coverage−3.2x−5.4x−3.2x−2.5x−2.2x
Current ratio14.3x8.9x5.7x5.4x5.3x
Quick ratio13.4x8.0x5.0x4.5x4.3x
US$ millions unless stated, at each fiscal year end. Net debt to EBITDA is debt minus cash, divided by operating income before depreciation and amortization: roughly how many years of those earnings the net debt equals. Debt to equity is debt as a multiple of shareholders' equity. Interest coverage is operating income divided by interest expense. The current ratio is current assets over current liabilities; the quick ratio leaves out inventory.

Cash flow

Cash from operations, capital spending and free cash flow
US$ billions, fiscal years. Free cash flow is cash from operations minus capital spending; negative years in red.
Cash from operationsCapital spendingFree cash flow
Stock-based compensation and buybacks
US$ billions, fiscal years. Shares paid to employees (stock-based compensation, a cost that uses no cash) against cash spent buying shares back. Buybacks that only match it leave the share count roughly where it was.
Stock-based compensationShare buybacks
Dividends and buybacks
US$ billions, cash paid in each fiscal year
DividendsShare buybacks
Diluted share count
Weighted-average diluted shares, millions

Projections

Project NeuroPace's revenue, net income and earnings per share five years ahead in a bull, a base and a bear case with your own figures, and see the share prices your P/E estimates give them, or value it with a discounted cash flow model. Every projected figure is yours: it is not a forecast of ours.

What NeuroPace says to expect

  • Full year 2026: total revenueRevise total revenue guidance for full year 2026 to between $91 million and $92 million, representing underlying RNS growth of 10% to 11%.
  • Full year 2026: non-GAAP operating expensesRevise full year non-GAAP operating expenses to be between $85 million and $86 million, compared to previous guidance of $90 million to $92 million.
  • Full year 2026: adjusted EBITDARevise Adjusted EBITDA to be between ($8.5) million and ($9.5) million compared to previous guidance between ($7.5) million to ($8.5) million.
The company's own words, from its earnings release (Form 8-K, Exhibit 99), filed November 12, 2026. They are its expectations, not ours, and not a forecast or price target from The Filing Desk. Replaced when the next release is out.

Insider trades

Over the 12 months between November 20, 2025 and November 19, 2026, 3 insiders bought $302,102 of NeuroPace shares on the open market, and 1 insider sold $399,250, all of it under trading plans set up in advance.

Buys and sells by month
US$ millions, open-market purchases (up) and sales (down) by officers, directors and 10% owners in each month.
BoughtSold
DateInsiderTradeSharesPriceValueFiling
Nov 18, 2026Huennekens R ScottDirectorBought12,500$8.29$103,661Form 4
Nov 17, 2026Joel BeckerChief Executive Officer, DirectorBought11,891$8.35$99,293Form 4
Nov 17, 2026Patrick F. WilliamsChief Financial OfficerBought11,891$8.34$99,148Form 4
Dec 15, 2025Martha MorrellChief Medical OfficerSold plan25,000$15.97$399,250Form 4
Open-market purchases and sales by officers, directors and 10% owners, from their Form 4 filings with the SEC: one row per person, day and filing, at the day's average price. Grants, option exercises and shares withheld for tax aren't counted. Insiders buy and sell for many reasons, such as taxes, spreading their savings or a plan set up months earlier, so a trade on its own says little about where a company is heading. For information only, not investment advice. Insider trades at all companies

Indicators

Four widely used measures, worked out from the company's filings. The cutoffs are the ones their authors or users go by, not a verdict of ours.

IndicatorFY23FY24FY25
Piotroski F-score4 of 94 of 95 of 9
Rule of 4013.3%−0.7%13.8%
Altman Z''−12.04−15.14−13.13
Accruals ratio−11.9%−9.1%−10.4%
Piotroski F-score: how many of nine simple tests of profitability, funding and efficiency the company passed in the year (Piotroski, 2000); 8 or 9 is strong, 0 to 2 weak. Rule of 40: revenue growth plus free cash flow margin; software investors treat 40% or more as the bar. Altman Z'': working capital, retained earnings, operating income and equity weighed against assets and liabilities (Altman, 1995); Altman puts above 2.6 in the safe zone and below 1.1 in the distress zone. Accruals ratio: net income minus cash from operations, over average total assets; lower means profit is backed by cash.

The nine F-score tests

TestFY23FY24FY25
Net income is positiveFailFailFail
Cash from operations is positiveFailFailFail
Return on assets rosePassPassPass
Cash from operations exceeds net incomePassPassPass
Debt fell relative to assetsFailFailPass
Current ratio roseFailFailFail
Share count didn't riseFailFailFail
Gross margin rosePassPassPass
Revenue rose relative to assetsPassPassPass
F-score4 of 94 of 95 of 9
Companies that report no gross profit are scored on the other eight.

Compare

Put NeuroPace side by side with any other company we cover: revenue, growth, margins, cash flow and returns, with ten years of charts.

Similar companies

CompanyYearRevenue growthOperating marginFree cash flow marginReturn on capitalNet debt to EBITDAF-scoreCompare
NeuroPaceFY2525.1%−16.3%−11.3%−81.8%—5
Beta BionicsFY2553.9%−71.5%−56.1%———Compare
Butterfly NetworkFY2519.0%−88.5%−16.4%———Compare
Sanara MedTechFY2519.0%7.1%2.1%13.0%2.6x3Compare
Kestra Medical TechnologiesFY2659.0%−141.6%−122.6%——4Compare
Each company's latest fiscal year. Fiscal years end in different months, so the periods don't line up exactly. Free cash flow margin is free cash flow as a share of revenue. Net debt to EBITDA is explained under the balance sheet, and the F-score under Indicators.

6 years of figures

Fiscal yearFY20FY21FY22FY23FY24FY25
Income statement
Revenue4145466580100
Revenue growth—9.8%0.8%43.7%22.1%25.1%
Gross profit303332485977
Research and development161822212428
Operating income−13−24−41−27−22−16
Net income−24−36−47−33−27−22
Diluted EPS (US$)−117.85−2.17−1.91−1.27−0.93−0.66
Diluted shares (millions)01725262933
Cash flow
Cash from operations−22−25−37−20−18−11
Capital expenditure001000
Free cash flow−22−25−37−20−18−11
Dividends paid000000
Share buybacks0000050
Acquisitions000000
Stock-based compensation148101011
Balance sheet at fiscal year end
Cash and short-term investments3811677665361
Debt incl. finance leases535053576059
Total assets5613411410895106
Total liabilities626079878786
Shareholders' equity−148743521819
Margins and ratios
Gross margin73.6%74.0%71.4%73.6%73.9%77.2%
Operating margin−31.7%−52.5%−89.6%−41.5%−27.1%−16.3%
Net margin−59.0%−79.8%−103.4%−50.4%−34.0%−21.5%
Free cash flow margin−52.7%−55.2%−82.3%−30.4%−22.9%−11.3%
Rule of 40 (growth + FCF margin)—−45.4%−81.6%13.3%−0.7%13.8%
Return on capital————−132.5%−81.8%
Return on equity——−87.0%−118.9%−189.3%−158.7%
Return on assets—−38.1%−38.0%−29.7%−26.8%−21.4%
Net debt to EBITDA——————
US$ millions unless stated. Where a later 10-K restated a year, the latest filed figure is shown. Download all figures (CSV, US$ millions)
Source: NeuroPace's Form 10-K filings, from SEC EDGAR. For information only, not investment advice. The Filing Desk is not affiliated with NeuroPace.